Ficus Technology Holdings Limited (FICUS TECH; 08107) reported interim results for the six months ended 30 June 2026 showing stronger top-line growth and a reduced loss, but net liabilities widened and going-concern risks persist.

Revenue and Profitability • Group revenue rose 21.1% year-on-year to HK$11.03 million, driven entirely by the Apparel & Other Products Supply-Chain Management (SCM) segment. • No revenue was generated from Construction Materials or Innovative SCM Solutions during the period. • Gross profit improved 26.8% to HK$0.65 million, lifting gross margin slightly to 5.9% (H1 2025: 5.7%). • Loss attributable to shareholders narrowed to HK$9.85 million from HK$13.55 million, reflecting higher sales and tighter cost control. • Selling and distribution expenses declined 57.3% to HK$0.12 million; administrative expenses fell 24.0% to HK$10.62 million. Finance costs dropped to zero after full repayment of bank borrowings in FY 2025.

Balance Sheet and Liquidity • Cash and cash equivalents stood at HK$0.13 million (31 Dec 2025: HK$0.37 million). Net current liabilities increased to HK$38.68 million, and total net liabilities reached HK$38.39 million. • Current ratio slipped to 0.41x (31 Dec 2025: 0.50x). The Group remains ungeared after settling all bank debt. • The auditor flagged material uncertainties over going concern. Mitigating plans include an undrawn US$25.00 million (HK$195.00 million) equity line of credit, HK$8.06 million shareholder loan support, and ongoing cost reductions.

Cash Flow • Operating activities generated net cash of HK$0.49 million versus an outflow of HK$6.58 million a year earlier. There were no investing or financing inflows in the period.

Operational Highlights • Two customers accounted for HK$11.00 million of revenue (99.7%), underscoring concentration risk. • June 2026 tender win: Shenzhen Sports Lottery Administration Centre promotional-gift project (budget cap RMB3.50 million; first order RMB1.89 million placed in July). • July 2026 framework agreement: Two-year annual procurement arrangement with Zhejiang Tianliang Biomedical Technology Co. covering Class II medical devices and other products; estimated annual volume RMB244.00 million with first order RMB4.40 million. • Share-based incentive: 97.50 million options (7.10% of issued shares) granted on 28 July 2026 at HK$0.112 strike, exercisable after 12 months.

Dividend No interim dividend was declared.

Outlook Management will focus on expanding its apparel SCM customer base in mainland China, executing recent government-related procurement wins, and maintaining strict cost discipline while monitoring liquidity options under the equity line facility.